In meta-analyses , tetrastarch vs. crystalloid or albumin lead to increased use of renal replacement therapy ( relative risk 1.36 , p = 0.009 ) and red blood cells ( relative risk 1.29 , p = 0.0002 ) and to more serious adverse events ( relative risk 1.30 , p = 0.03 ) .